1. Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study.
- Author
-
Ibrahim, Mahmoud A. A., Abdeljawaad, Khlood A. A., Abdelrahman, Alaa H. M., Jaragh-Alhadad, Laila A., Oraby, Hesham Farouk, Elkaeed, Eslam B., Mekhemer, Gamal A. H., Gabr, Gamal A., Shawky, Ahmed M., Sidhom, Peter A., Soliman, Mahmoud E. S., Moustafa, Mahmoud F., Paré, Paul W., and Hegazy, Mohamed-Elamir F.
- Subjects
DRUG discovery ,P-glycoprotein ,NATURAL products ,MOLECULAR dynamics ,MOLECULAR docking - Abstract
The P-glycoprotein (P-gp/ABCB1) is responsible for a xenobiotic efflux pump that shackles intracellular drug accumulation. Additionally, it is included in the dud of considerable antiviral and anticancer chemotherapies because of the multidrug resistance (MDR) phenomenon. In the search for prospective anticancer drugs that inhibit the ABCB1 transporter, the Natural Product Activity and Species Source (NPASS) database, containing >35,000 molecules, was explored for identifying ABCB1 inhibitors. The performance of AutoDock4.2.6 software to anticipate ABCB1 docking score and pose was first assessed according to available experimental data. The docking scores of the NPASS molecules were predicted against the ABCB1 transporter. Molecular dynamics (MD) simulations were conducted for molecules with docking scores lower than taxol, a reference inhibitor, pursued by molecular mechanics-generalized Born surface area (MM-GBSA) binding energy estimations. On the basis of MM-GBSA calculations, five compounds revealed promising binding affinities as ABCB1 inhibitors with ΔG
binding < −105.0 kcal/mol. The binding affinity and stability of the identified inhibitors were compared to the chemotherapeutic agent. Structural and energetical analyses unveiled great steadiness of the investigated inhibitors within the ABCB1 active site throughout 100 ns MD simulations. Conclusively, these findings point out that NPC104372, NPC475164, NPC2313, NPC197736, and NPC477344 hold guarantees as potential ABCB1 drug candidates and warrant further in vitro/in vivo tests. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF